Table 2.
Clinicopathological factors | PD-1 in tumor | PD-1 in TIL | PD-L1 in tumor | PD-L1 in TIL | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||||
Negative (n = 17) | Positive (n = 37) | p-value | Negative (n = 16) | Positive (n = 38) | p-value | Negative (n = 17) | Positive (n = 37) | p-value | Negative (n = 42) | Positive (n = 12) | p-value | |
Age (years) | ||||||||||||
≤ 50 | 9 | 14 | 0.29 | 9 | 11 | 0.058 | 7 | 16 | 0.88 | 15 | 8 | 0.056 |
> 50 | 8 | 23 | 7 | 27 | 10 | 21 | 27 | 4 | ||||
Sex | ||||||||||||
Male | 8 | 27 | 0.064 | 8 | 27 | 0.13 | 12 | 23 | 0.54 | 28 | 7 | 0.84 |
Female | 9 | 10 | 8 | 11 | 5 | 14 | 14 | 5 | ||||
Tumor size | ||||||||||||
≤ 5 cm | 6 | 15 | 0.71 | 7 | 14 | 0.63 | 6 | 15 | 0.71 | 17 | 4 | 0.91 |
> 5 cm | 11 | 22 | 9 | 24 | 11 | 22 | 25 | 8 | ||||
Tumor location | ||||||||||||
Sacral vertebra | 13 | 29 | 1.00 | 11 | 31 | 0.49 | 14 | 28 | 0.84 | 32 | 10 | 0.89 |
Cervical or thoracic or lumbar vertebra | 4 | 8 | 5 | 7 | 3 | 9 | 10 | 2 | ||||
Surrounding muscle invasion | ||||||||||||
Yes | 9 | 27 | 0.14 | 8 | 28 | 0.092 | 11 | 25 | 0.83 | 29 | 7 | 0.72 |
No | 8 | 10 | 8 | 10 | 6 | 12 | 13 | 5 | ||||
Preoperative recurrence | ||||||||||||
Yes | 5 | 6 | 0.45 | 4 | 7 | 0.85 | 6 | 5 | 0.13 | 6 | 5 | 0.095 |
No | 12 | 31 | 12 | 31 | 11 | 32 | 36 | 7 | ||||
Grade | ||||||||||||
High | 12 | 26 | 0.98 | 12 | 26 | 0.87 | 15 | 23 | 0.051 | 27 | 11 | 0.14 |
Low | 5 | 11 | 4 | 12 | 2 | 14 | 15 | 1 | ||||
Stagea | ||||||||||||
IA | 5 | 8 | 0.97 | 4 | 9 | 0.38 | 2 | 11 | 0.041 | 12 | 1 | 0.23 |
IB | 2 | 4 | 1 | 5 | 0 | 6 | 6 | 0 | ||||
IIA | 0 | 4 | 0 | 4 | 3 | 1 | 2 | 2 | ||||
IIB | 8 | 19 | 9 | 18 | 9 | 18 | 18 | 9 | ||||
III | 2 | 2 | 2 | 2 | 3 | 1 | 4 | 0 | ||||
Type of resection | ||||||||||||
EI | 4 | 14 | 0.30 | 3 | 15 | 0.14 | 5 | 13 | 0.67 | 17 | 1 | 0.083 |
EA | 13 | 23 | 13 | 23 | 12 | 24 | 25 | 11 | ||||
Tumor hemorrhage | ||||||||||||
No | 4 | 6 | 0.79 | 4 | 6 | 0.68 | 3 | 7 | 1.00 | 7 | 3 | 0.81 |
Yes | 13 | 31 | 12 | 32 | 14 | 30 | 35 | 9 | ||||
Tumor necrosisb | ||||||||||||
Absent | 4 | 9 | 0.42 | 3 | 10 | 0.64 | 4 | 9 | 0.41 | 10 | 3 | 0.34 |
Mild | 8 | 10 | 6 | 12 | 5 | 13 | 16 | 2 | ||||
Moderate | 3 | 12 | 4 | 11 | 3 | 12 | 11 | 4 | ||||
Severe | 2 | 6 | 3 | 5 | 5 | 3 | 5 | 3 | ||||
Extent of TILs | ||||||||||||
Negative | 9 | 14 | 0.29 | 10 | 13 | 0.055 | 12 | 11 | 0.005 | 16 | 7 | 0.21 |
Positive | 8 | 23 | 6 | 25 | 5 | 26 | 26 | 5 | ||||
Ki-67 index | ||||||||||||
Low | 10 | 15 | 0.21 | 8 | 17 | 0.72 | 8 | 17 | 0.93 | 19 | 6 | 0.77 |
High | 7 | 22 | 8 | 21 | 9 | 20 | 23 | 6 |
EI, Enneking inappropriate; EA, Enneking appropriate; TILs, tumor-infiltrating lymphocytes; PD-1, programmed cell death 1; PD-L1, programmed cell death-1 ligand 1.
Wilcoxon rank sum test.
Wilcoxon rank sum test.